Ranluspec is the only interchangeable ranibizumab biosimilar approved in the United States in both vial and pre-filled syringe (PFS) presentations
The drug currently approved for chronic kidney disease (CKD) associated with type 2 diabetes, may benefit a much broader group of patients than previously recognized
Approval for generic version of Xeljanz enables immediate launch and strengthens Aurobindo’s U.S. portfolio with its 586th ANDA approval
Company expands injectable portfolio with therapeutically equivalent version of Vimpat®, targeting a market valued at approximately $15.2 million annually
Teva said the launch strengthens its biosimilars strategy and expands access to biologic medicines across Europe
Targeting deadly drug-resistant acinetobacter infections
Highlights potential for at-home heart attack risk assessment, offering a new approach to reducing treatment delays
The facility integrates advanced scientific infrastructure and specialised workflows to support complex drug delivery systems, sterile injectables, and differentiated dosage forms
The ventilator features a high-performance turbine capable of delivering up to 240 L/min peak flow
Following the completion of the acquisition on June 3, Noctrix’s flagship product, Nidra will become part of ResMed’s broader sleep medicine portfolio
Subscribe To Our Newsletter & Stay Updated
